LY 426965

Drug Profile

LY 426965

Latest Information Update: 01 Aug 2002

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Lundbeck Research USA
  • Class Antidepressants; Anxiolytics; Drug withdrawal therapies; Piperidines; Smoking cessation therapies
  • Mechanism of Action Serotonin 1A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Drug abuse; Major depressive disorder; Smoking withdrawal

Most Recent Events

  • 19 Jan 2000 Preclinical development for Drug abuse in USA (Unknown route)
  • 19 Jan 2000 Preclinical development for Depression in USA (Unknown route)
  • 19 Jan 2000 Preclinical development for Smoking withdrawal in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top